ArticleCurrent oncology (Toronto, Ont.)2025

First-Line Pyrotinib Combination Therapy for HER2-Mutated Advanced NSCLC: A Retrospective Cohort Analysis.

Yan Xiang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.